Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-07-27
2009-12-08
Aeder, Sean E (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
07629325
ABSTRACT:
A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors (e.g., skin caner) are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion being capable of inhibiting RTK-mediated cell proliferation and whereas upregulating can be effected by: expressing in cells of the subject an exogenous polynucleotide encoding at least a functional portion of Sef (e.g., SEQ ID NOs:4, 8 or 9); increasing expression of endogenous Sef in cells of the subject; increasing endogenous Sef activity in cells of the subject; and introducing an exogenous peptide and/or exogenous polypeptide including at least a functional portion of Sef to the subject. Also provided are methods and kits for diagnosing and staging of cancer (e.g., breast cancer, thyroid cancer, prostate cancer) by detecting the expression level of hSef in a tissue sample, wherein a decrease in hSef expression level is indicative of cancer.
REFERENCES:
patent: 2004/0235104 (2004-11-01), Yang
patent: 2004/0260389 (2004-12-01), Case et al.
patent: 2004/0265834 (2004-12-01), Xiong et al.
patent: 2006/0079444 (2006-04-01), Ron
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Rolland (Advanced Drug Delivery Reviews, 2005, 57:669-673).
Gura (Science, 1997, 278:1041-1042.).
Lang et al (J. Clin. Oncol., 2003, 21: 2508-2518).
Guan et al (World J. Gastroenterol., 2005, 11: 3803-3805).
Mahendra et al (Cancer Gene Therapy, 2005, 12:26-3).
Kitsberg et al. “Keratinocyte Growth Factor Induces Mammary and Prostatic Hyperplasia and Mammary Adenocarcinoma in Transgenic Mice”, Oncogene, 13, p. 2507-2515, 1996.
Kovalenko et al. “Sef Inhibits Fibroblast Growth Factor Signaling by Inhibiting FGFR1 Tyrosine Phosphorylation and Subsequent ERK Activation”, J. Biol. Chem., vol. 278 (16) p. 14087-14091, 2003.
Lin et al. “Cloning of the Mouse Sef Gene and Comparative analysis of its Expression with Fgf8 and Spry2 During Embryogenesis”, Mech. Dev. 113, 163-168, 2002.
MCKeehan et al. “The Heparan Sulfate-Fibroblast Growth Factor Family: Diversity of Structure and Function”, Medline, Prog. Nucleic Acid. Res. Mol. Biol, vol. 59 p. 135-176, 1998. Abstract.
Shaoul et al. “Fibroblast Growth Factor Receptors Display Both Common and Distinct Signaling Pathways”, Oncogene, 10: 1553-1561, 1995.
Siddiqi et al. “Increased Expression of Keratinocyte Growth Factor in Human Pancreatic Cancer”, Biochemical and Biophysical Reaserch Communications, vol. 215 (1): p. 309-315, 1995.
Siegfried et al. “Distinct Patterns of Expression of Keratinocyte Growth Factor and its Receptor in Endometrial Carcinoma”,Cancer vol. 79 p. 1166-1171, 1997.
Toru et al. “Expression cDNA Cloning of the KGF Receptor by Creation of a Transforming Autocrine Loop”, Science, vol. 251, p. 72-75, 1991.
Tsang et al. “Identification of Sef, A Novel Modulator of FGF Signalling”, Nature Cell Biology, vol. 4, 2002.
Visco et al. “Expression of Keratinocyte Growth Factor Receptor Compared with that of Epidermal Growth Factor Receptor and erbB-2 in Endometrial Adenocarcinoma”, International Journal of Oncology, vol. 15, p. 431-435, 1999.
Xiong et al. “hSef Inhibits PC-12 Cell Differentiation by Interfering With Ras-Mitogen-Activated Protein Kinase MAPK Signaling”, Journal of Biological Chemistry, vol. 258 (50): p. 50273-50282, 2003.
Yang et al. “A Novel Interleukin-17 Rceptor-Like protein Idetified in Human Umbilical Vein Endothelial Cells Antagnoizes Basic Fibroblast Growth Factor-Induced signaling”, Journal of Biol. Chem., vol. 278 (35), p. 33232-8, 2003.
Zetter “Angiogenesis And Tumor Metastasis”, Annual Reveiw of Medicine vol. 409: p. 407-424, 1998.
Zisman-Rozen et al. “Downregulation of sef, an Inhibitor of Receptor Tyrosine Kinase Signaling, is Common to a Variety of Human Carcinomas”, oncogene, vol. 26: p. 6093-6098, 2007.
Aeder Sean E
Technion Research & Development Foundation Ltd.
LandOfFree
Human Sef isoforms and methods of using same for cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human Sef isoforms and methods of using same for cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human Sef isoforms and methods of using same for cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4122148